Symptomatic Aortic Bare-Metal Stent Fracture after PETTICOAT Technique for Complicated Type B Aortic Dissection

2019 ◽  
Vol 59 ◽  
pp. 311.e1-311.e4 ◽  
Author(s):  
África Duque Santos ◽  
Andrés Reyes Valdivia ◽  
Sergio Gordillo Alguacil ◽  
Julia Ocaña Guaita ◽  
Claudio Gandarias Zúñiga
Keyword(s):  
Aortic Dissection ◽  
Bare Metal Stent ◽  
Stent Fracture ◽  
Bare Metal ◽  
Type B ◽  
Metal Stent ◽  
Type B Aortic Dissection

scholarly journals Bare Metal Stent Use in Type B Aortic Dissection May Offer Positive Remodeling for the Distal Aorta

2018 ◽  
Vol 106 (5) ◽  
pp. 1364-1370 ◽  
Author(s):  
Ibrahim Sultan ◽  
Keith Dufendach ◽  
Arman Kilic ◽  
Valentino Bianco ◽  
Dhaval Trivedi ◽  
...  
Keyword(s):  
Aortic Dissection ◽  
Bare Metal Stent ◽  
Bare Metal ◽  
Type B ◽  
Metal Stent ◽  
Type B Aortic Dissection

scholarly journals Positive Remodeling of the Aorta Using Bare Metal Stent in Acute Type B Aortic Dissection

2019 ◽  
Author(s):  
S. Buz ◽  
A. Navasardyan ◽  
A. Unbehaun ◽  
M.-T. Nazari-Shafti ◽  
V. Falk
Keyword(s):  
Aortic Dissection ◽  
Bare Metal Stent ◽  
Acute Type ◽  
Bare Metal ◽  
Type B ◽  
Metal Stent ◽  
Type B Aortic Dissection

Distal bare metal stent implantation during thoracic endovascular aortic repair is beneficial to treat complicated type B aortic dissection: A systematic review and meta-analysis

Vascular ◽  
2020 ◽  
pp. 170853812096840
Author(s):  
Xuanzhu Kong ◽  
Li Peng ◽  
Fengrui Wu ◽  
Jiaxue Bi ◽  
Hongrui Pan ◽  
...  
Keyword(s):  
Adverse Events ◽  
Aortic Dissection ◽  
Statistical Method ◽  
Bare Metal Stent ◽  
Thoracic Endovascular Aortic Repair ◽  
Endovascular Aortic Repair ◽  
Bare Metal ◽  
Type B ◽  
Metal Stent ◽  
Type B Aortic Dissection

Objective To explore whether thoracic endovascular aortic repair (TEVAR) plus distal bare metal stent (BMS) implantation leads to favorable clinical outcomes compared with standard TEVAR in treating acute complicated type B aortic dissection. Methods Relevant publications were found through a precise search of PubMed, Cochrane Library, and EMBASE. Count data were calculated as the odd ratio (OR)and 95% confidence interval (CI) using the Mantel–Haenszel statistical method, quantitative data were calculated as mean difference and 95% CI using Inverse Variance statistical method. When the data heterogeneity was large, with an I2 > 50%, a random-effects model and sensitivity analysis were performed. The analysis tool we used was the software Revman 5.3 and G*power 3.1. Results There were 7 publications involving 958 patients who were enrolled ultimately. The incidence of unplanned secondary intervention and postoperative adverse events in the TEVAR + BMS were lower than standard TEVAR (OR, 0.42, (95% CI, 0.23 to 0.75); OR, 0.57, (95% CI, 0.37 to 0.90)), and the pooled number needed to treat was 15 for unplanned secondary intervention and 15 for postoperative adverse events. There were no significant difference in the aortic-related or all-cause 30-day mortality (OR, 0.81, (95% CI, 0.25 to 2.61); OR, 0.47, (95% CI, 0.18 to 1.22)), aortic-related, all-cause mortality at least 6 months or incidence of the postoperative endoleak (OR, 0.47, (95% CI, 0.17 to 1.32); OR, 0.42, (95% CI, 0.17 to 1.06); OR, 0.81, (95% CI, 0.32 to 2.05)). Conclusion There is no significant outcome difference except for reduced reintervention but this does not seem to adversely affect survival. It is unclear whether this justifies the additional cost of placing it in every complicated type B aortic dissection regardless of anatomy after standard TEVAR alone. Besides, more data are needed to verify the adjunctive distal bare metal stents’ performance at different dissection stages.

scholarly journals BARE METAL STENT IMPLANTATION IN TREATING DISTAL AORTIC DISSECTION: A CASE REPORT

2018 ◽  
Vol 5 (5) ◽  
pp. 12-17 ◽  
Author(s):  
M. A. Chernyavskiy ◽  
B. S. Artyushin ◽  
A. V. Chernov ◽  
Yu. A. Kudaev ◽  
D. V. Chernova ◽  
...  
Keyword(s):  
Case Report ◽  
Aortic Dissection ◽  
Stent Implantation ◽  
Open Surgery ◽  
Stent Migration ◽  
Bare Metal Stent ◽  
Thoracic Endovascular Aortic Repair ◽  
Bare Metal ◽  
Metal Stent ◽  
Second Stage

This article demonstrates a case of effective and save endovascular treatment of distal aortic dissection and underlines its advantages over open surgery. The case describes successful implantation of bare metal stent into abdominal aorta. The patient of 78 years old underwent thoracic endovascular aortic repair as first stage, then bare metal stent implantation as second stage. There were no complications. CT-scan in 3 month showed no endoleaks or stent migration.

scholarly journals Paclitaxel Coated Balloon vs. Bare Metal Stent for Endovascular Treatment of Symptomatic Vertebral Artery Origin Stenosis Patients: Protocol for a Randomized Controlled Trial

2021 ◽  
Vol 11 ◽  
Author(s):  
Yabing Wang ◽  
Yan Ma ◽  
Peng Gao ◽  
Yanfei Chen ◽  
Bin Yang ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Vertebral Artery ◽  
Safety Data ◽  
Target Lesion ◽  
Bare Metal Stent ◽  
Stent Fracture ◽  
Bare Metal ◽  
Metal Stent ◽  
Binary Restenosis ◽  
Randomized Controlled

Background: Stenting treatment for refractory symptomatic patients with vertebral artery origin stenosis (VAOS) is safe; however, there is a high rate of in-stent restenosis. Although drug-eluting stents can reduce the incidence of restenosis to some extent, there is still a risk caused by stent fracture. Drug-coated balloon (DCB) has been proven to reduce the rate of restenosis in peripheral and coronary artery disease. DCB can prevent inflammation caused by extraneous material stimulation and allow the subsequent treatment that is characteristic of “leave nothing behind.” The purpose of this trial is to compare the efficacy and safety of DCB and bare metal stent (BMS) in the treatment of VAOS.Method/Design: This trial is a 1:1 randomized, controlled, multicenter, non-inferiority trial that compares the DCB to BMS in terms of angiographically assessed target lesion binary restenosis (≥50%) at 12 months in endovascular treatment of symptomatic patients with VAOS.Discussion: A total of 180 patients with symptomatic VAOS who match the trial eligibility criteria will be randomized 1:1 to treatment with DCB (n = 90) or BMS (n = 90). An angiographic core laboratory-adjudicated target lesion binary restenosis (≥50%) at 12 months of follow-up was selected as primary efficacy endpoint to assess the DCB treatment effect. A clinical events committee will assess the safety endpoints of all-cause death, target vessel related transient ischemic attack and ischemic or hemorrhagic stroke events. A data safety monitoring board will periodically review safety data for subject safety, the study conduct, and progress. In this trial, randomization is only allowed after successful pre-dilatation. We anticipate that this trial will provide rigorous data to clarify whether DCBs are beneficial in patients with symptomatic VAOS.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03910166.

Sign in / Sign up

Export Citation Format

Share Document